Cargando…
New Drug Updates in Hematologic Malignancies: CAR-T, Targeted Therapeutics, and Other Agents
FDA approvals for hematologic malignancies from 2016 to 2017 can be grouped in three themes: personalized small molecules, immunotherapies, and new formulations or modes of delivery for conventional agents. The unique profiles of these drugs, including that of CAR-T cell therapy, are summarized.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333553/ |